Johnson & Johnson To Co-Promote Cephalon's ADHD Treatment Modafinil
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal allows J&J to opt out if its own attention deficit/hyperactivity disorder therapy Concerta loses exclusivity.